Sign in Subscribe

GSK Buys Experimental Multiple Myeloma Drug from Chimagen

GSK will buy a Chimagen trispecific T-cell engager for multiple myeloma. Phase I trials start in 2027. The deal is worth up to $750 million.

GSK Buys Experimental Multiple Myeloma Drug from Chimagen
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Already have an account? Sign in.